Nyxoah SA (EBR:NYXH)

Market Cap	201.78M
Revenue (ttm)	4.93M
Net Income (ttm)	-77.20M
Shares Out	37.44M
EPS (ttm)	-2.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,231
Average Volume	111,768
Open	5.49
Previous Close	5.39
Day's Range	5.26 - 5.49
52-Week Range	5.03 - 10.90
Beta	0.65
RSI	38.75
Earnings Date	Aug 6, 2025

About Nyxoah

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 184
• Stock Exchange: Euronext Brussels
• Ticker Symbol: NYXH

Financial Performance

In 2024, Nyxoah's revenue was 4.52 million, an increase of 3.98% compared to the previous year's 4.35 million. Losses were -59.24 million, 37.1% more than in 2023.